Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomized controlled trial.

Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C and Linn T

29/03/2008

The Lancet, 371 (9618), 1073-1084.